Literature DB >> 6152317

Physical dependence induced by opiate partial agonists in the rat.

P S McCarthy, G J Howlett.   

Abstract

The ability of four opiate partial agonists (buprenorphine, xorphanol, nalbuphine and butorphanol) to produce antinociception and morphine-like physical dependence was examined in the rat. For comparative purposes, morphine was also tested. Dose-response curves were constructed using the rat tail pressure test for analgesia which indicated a rank order of potency of buprenorphine much greater than morphine greater than butorphanol greater than xorphanol = nalbuphine. Assessment of primary physical dependence liability was made using the technique of chronic intraperitoneal infusion followed by precipitation of abstinence with the opiate antagonist, naloxone. The results clearly indicate that buprenorphine was not only the most potent antinociceptive agent, but also possessed the lowest incidence of physical dependence as indicated by precipitated abstinence signs. The other opiates were very much weaker as antinociceptive agents and all produced clear signs of physical dependence.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6152317     DOI: 10.1016/0143-4179(84)90014-3

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.

Authors:  H Fukase; K Fukuzaki; T Koja; R Nagata; S E Lukas
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

2.  Mu- and delta-opioid receptor antagonists precipitate similar withdrawal phenomena in butorphanol and morphine dependence.

Authors:  Y Z Feng; T Zhang; S Tokuyama; H Zhu; R W Rockhold; I K Ho
Journal:  Neurochem Res       Date:  1996-01       Impact factor: 3.996

3.  Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.

Authors:  Parham Gharagozlou; Hasan Demirci; J David Clark; Jelveh Lameh
Journal:  BMC Neurosci       Date:  2002-11-18       Impact factor: 3.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.